Thermo Fisher Scientific announces Oncomine Clinical Research Grant awardees and opens Spring 2023 submissions
Thermo Fisher Scientific announced the latest recipients of the Oncomine Clinical Research Grant and the opening of its submissions for Spring 2023. Grant recipients are leading the exploration of new and expanded applications for next-generation sequencing (NGS)-based testing so that more cancer patients can access the benefits of precision medicine.
Based on the last call for proposals in the fall, the following researchers and projects have been selected as the newest grant recipients:
- Monica Lopez-Guerra, Hospital Clinic, Barcelona, Spain - “Molecular measurable residual disease (MRD) monitoring by high-throughput techniques in patients with CART 19 therapy”
- Estrid Høgdall, Herlev University Hospital, Herlev, Denmark - “HRD biomarker: Qualification and implementation of validated local HRD test”
- Paul Hofman, University of Côte d’Azur, France - “Comprehensive molecular characterization of early-stage NSCLC with KRAS G12C mutation using ODxET*”
This fall, current and former recipients of the Oncomine Clinical Research Grant will have the opportunity to attend a closed scientific gala to share their research with the wider pharmaceutical community.
Grant applications are open now through May 15th, 2023, and proposals should recognize the planned activities to be performed within a maximum of 12 months, as well as an outline of the proposed use of the requested funds. Oncomine Grants are available for clinical research projects focusing on molecular testing in oncology and reproductive health. For more information on the Oncomine Clinical Research Grant Program and how to submit proposals, please visit www.oncomine.com/grants.
